FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2558456064> ?p ?o ?g. }

• W2558456064 abstract "Abstract Abstract 5047 Introduction: Treatment of myeloma bone disease with bisphosphonates (BP) is standard of care. However, renal toxicity due to BP treatment tends to be a major problem in myeloma patients, especially. At highest risk are patients with reduced renal function and patients who had switched the BP. Toxicity appears typically after few month of BP treatment. We evaluated the renal safety of ibandronate (IBD) in myeloma patients, who were treated with IBD for myeloma bone disease. The patients were stratified according to pretreatment and kidney function. Methods: In a prospective noninterventional study about safety and efficacy of IBD in breast cancer patients it turned out that myeloma patients were also included unintentionally. Out of 3540 documented patients 105 myeloma patients were identified. The data from these myeloma patients were evaluated separately. The patients were subdivided in 4 groups according to their glomerular filtration rate [GFR]: GFR>90 (1), 60–90 (2), 30–59 (3) and <30 (4) ml/min. Since pretreatment with other BP could be of influence, patients were analysed according to former pretreatment: no BP (I), IBD (II), and other BP (III). The renal function was calculated every month over a period of six month by the MDRD-formula. Results: 105 patients were available for evaluation. In 99 patients RF was documented over a minimum of 5 months. The initial RF was (1) n=14, (2) n=36, (3) n=38 and (4) n=17, respectively. At baseline there were no differences in renal function according to their pretreatment. A total number of 692 infusions were documented. The IBD dosage was 6 mg in 90% of all infusions, 4 mg in 3,6%, 3 mg in 2% and 2 mg in 4.4%, respectively. The GFR (mean GFR+/−SD) was stable over time in the groups 1–3 and increased significantly in group 4; The mean changes were similar in all groups irrespectively of the pretreatment. In 9 patients the treatment was terminated prematurely, due to disease progression (n=3), death due to myeloma during study period (n=3). Two patients were lost by follow up and one patient declined further treatment. Discussion: The data of this noninterventional study demonstrate, that there is no evidence for renal toxicity of IBD in myeloma patients in all stages of renal function. Quite in contrary to previous observations with other BP patients with worse kidney function (stage 4) had a significant improvement of GFR over the study period. The reason for this observation remains unclear, because parameters like hypercalcemia or burden of light chains are not recorded in this study. Disclosures: Off Label Use: Ibandronate is not approved for myeloma bone diease." @default.
• W2558456064 created "2016-12-08" @default.
• W2558456064 creator A5036936763 @default.
• W2558456064 creator A5060928496 @default.
• W2558456064 creator A5076567029 @default.
• W2558456064 creator A5081423944 @default.
• W2558456064 creator A5083776781 @default.
• W2558456064 date "2010-11-19" @default.
• W2558456064 modified "2023-09-30" @default.
• W2558456064 title "Ibandronate and Renal Function In Myeloma Patients" @default.
• W2558456064 doi "https://doi.org/10.1182/blood.v116.21.5047.5047" @default.
• W2558456064 hasPublicationYear "2010" @default.
• W2558456064 type Work @default.
• W2558456064 sameAs 2558456064 @default.
• W2558456064 citedByCount "0" @default.
• W2558456064 crossrefType "journal-article" @default.
• W2558456064 hasAuthorship W2558456064A5036936763 @default.
• W2558456064 hasAuthorship W2558456064A5060928496 @default.
• W2558456064 hasAuthorship W2558456064A5076567029 @default.
• W2558456064 hasAuthorship W2558456064A5081423944 @default.
• W2558456064 hasAuthorship W2558456064A5083776781 @default.
• W2558456064 hasConcept C126322002 @default.
• W2558456064 hasConcept C126894567 @default.
• W2558456064 hasConcept C141071460 @default.
• W2558456064 hasConcept C159641895 @default.
• W2558456064 hasConcept C2776169692 @default.
• W2558456064 hasConcept C2776364478 @default.
• W2558456064 hasConcept C2776541429 @default.
• W2558456064 hasConcept C2778653478 @default.
• W2558456064 hasConcept C29730261 @default.
• W2558456064 hasConcept C71924100 @default.
• W2558456064 hasConcept C90924648 @default.
• W2558456064 hasConceptScore W2558456064C126322002 @default.
• W2558456064 hasConceptScore W2558456064C126894567 @default.
• W2558456064 hasConceptScore W2558456064C141071460 @default.
• W2558456064 hasConceptScore W2558456064C159641895 @default.
• W2558456064 hasConceptScore W2558456064C2776169692 @default.
• W2558456064 hasConceptScore W2558456064C2776364478 @default.
• W2558456064 hasConceptScore W2558456064C2776541429 @default.
• W2558456064 hasConceptScore W2558456064C2778653478 @default.
• W2558456064 hasConceptScore W2558456064C29730261 @default.
• W2558456064 hasConceptScore W2558456064C71924100 @default.
• W2558456064 hasConceptScore W2558456064C90924648 @default.
• W2558456064 hasLocation W25584560641 @default.
• W2558456064 hasOpenAccess W2558456064 @default.
• W2558456064 hasPrimaryLocation W25584560641 @default.
• W2558456064 hasRelatedWork W1583692985 @default.
• W2558456064 hasRelatedWork W1968833887 @default.
• W2558456064 hasRelatedWork W1994249743 @default.
• W2558456064 hasRelatedWork W2006954817 @default.
• W2558456064 hasRelatedWork W2100630464 @default.
• W2558456064 hasRelatedWork W2128240436 @default.
• W2558456064 hasRelatedWork W2232870287 @default.
• W2558456064 hasRelatedWork W2281065280 @default.
• W2558456064 hasRelatedWork W2403486663 @default.
• W2558456064 hasRelatedWork W2583115655 @default.
• W2558456064 hasRelatedWork W2593081121 @default.
• W2558456064 hasRelatedWork W2752085549 @default.
• W2558456064 hasRelatedWork W2953192301 @default.
• W2558456064 hasRelatedWork W2980732629 @default.
• W2558456064 hasRelatedWork W3034760477 @default.
• W2558456064 hasRelatedWork W3043407203 @default.
• W2558456064 hasRelatedWork W3098483946 @default.
• W2558456064 hasRelatedWork W3163473741 @default.
• W2558456064 hasRelatedWork W3184170578 @default.
• W2558456064 hasRelatedWork W3201707959 @default.
• W2558456064 isParatext "false" @default.
• W2558456064 isRetracted "false" @default.
• W2558456064 magId "2558456064" @default.
• W2558456064 workType "article" @default.